within Pharmacolibrary.Drugs.ATC.M;

model M09AX03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.56,
    Cl             = 7.999999999999999e-05,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.109,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005849999999999999,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M09AX03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ataluren is a small molecule drug designed to promote ribosomal readthrough of nonsense mutations in genetic diseases. It is indicated for the treatment of Duchenne muscular dystrophy (DMD) caused by nonsense mutations in the dystrophin gene and has conditional approval in some countries, such as the EU, for ambulatory patients aged two years and older.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for ambulatory male patients (children and adults) with Duchenne muscular dystrophy, after single and multiple oral doses.</p><h4>References</h4><ol><li><p>Kong, R, Laskin, OL, Kaushik, D, Jin, F, Ma, J, McIntosh, J, Souza, M, &amp; Almstead, N (2019). Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects. <i>Clinical pharmacology in drug development</i> 8(2) 172–178. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.645&quot;>10.1002/cpdd.645</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30629861/&quot;>https://pubmed.ncbi.nlm.nih.gov/30629861</a></p></li><li><p>Kong, R, Ma, J, Hwang, S, Goodwin, E, Northcutt, V, Babiak, J, Almstead, N, &amp; McIntosh, J (2020). Metabolism and Disposition of Ataluren after Oral Administration to Mice, Rats, Dogs, and Humans. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 48(4) 317–325. DOI:<a href=&quot;https://doi.org/10.1124/dmd.119.089391&quot;>10.1124/dmd.119.089391</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31980502/&quot;>https://pubmed.ncbi.nlm.nih.gov/31980502</a></p></li><li><p>Sermet-Gaudelus, I, Boeck, KD, Casimir, GJ, Vermeulen, F, Leal, T, Mogenet, A, Roussel, D, Fritsch, J, Hanssens, L, Hirawat, S, Miller, NL, Constantine, S, Reha, A, Ajayi, T, Elfring, GL, &amp; Miller, LL (2010). Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. <i>American journal of respiratory and critical care medicine</i> 182(10) 1262–1272. DOI:<a href=&quot;https://doi.org/10.1164/rccm.201001-0137OC&quot;>10.1164/rccm.201001-0137OC</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20622033/&quot;>https://pubmed.ncbi.nlm.nih.gov/20622033</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M09AX03;
